Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. by Kesari, Santosh & Ram, Zvi
Providence St. Joseph Health
Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
7-1-2017
Tumor-treating fields plus chemotherapy versus
chemotherapy alone for glioblastoma at first
recurrence: a post hoc analysis of the EF-14 trial.
Santosh Kesari
Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute at Providence Saint John's
Health Center
Zvi Ram
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Neurology Commons, and the Oncology Commons
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles,
Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact
digitalcommons@providence.org.
Recommended Citation
Kesari, Santosh and Ram, Zvi, "Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first
recurrence: a post hoc analysis of the EF-14 trial." (2017). Articles, Abstracts, and Reports. 1602.
https://digitalcommons.psjhealth.org/publications/1602
185ISSN 2045-0907
part of
CNS Oncology
10.2217/cns-2016-0049 © 2017 Future Medicine Ltd
CliniCal Trial EvaluaTion
Tumor-treating fields plus chemotherapy 
versus chemotherapy alone for 
glioblastoma at first recurrence:  
a post hoc analysis of the EF-14 trial
Santosh Kesari*,1,2,3 & Zvi Ram4; on behalf of EF-14 Trial Investigators
1Translational Neuro-Oncology Laboratories, UC San Diego, San Diego, CA, USA 
2Department of Neurosciences, UC San Diego, San Diego, CA, USA 
3Department of Translational Neurosciences & Neurotherapeutics, Pacific Neuroscience Institute & John Wayne Cancer Institute at 
Providence Saint John’s Health Center, Santa Monica, CA, USA 
4Neurosurgery Department, The Tel Aviv Sourasky Medical Center & Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel 
*Author for correspondence: Tel.: +1 310 829 8265; Fax: +1 310 582 7287; kesaris@jwci.org
Background: This post hoc analysis of the EF-14 trial (NCT00916409) of tumor-treating fields 
(TTFields) plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma 
compared the efficacy of TTFields plus chemotherapy (physician’s choice) versus 
chemotherapy alone after first recurrence. Methods: Patients on TTFields plus temozolo-
mide continued TTFields plus second-line chemotherapy after first recurrence. Some 
patients on temozolomide alone crossed over after approval of TTFields for recurrent GBM. 
The primary efficacy outcome was overall survival (OS). results: After disease progression, 
131 patients received TTFields plus chemotherapy and 73 chemotherapy alone. Thirteen 
patients in the original temozolomide-alone group crossed over to receive TTFields plus 
chemotherapy after disease progression, resulting in 144 patients receiving TTFields plus 
chemotherapy and 60 chemotherapy alone. Median follow-up was 12.6 months. Bevacizumab, 
alone or with cytotoxic chemotherapy, was the most frequent treatment. Median OS in the 
TTFields plus chemotherapy group was significantly longer versus chemotherapy alone (11.8 
vs 9.2 months; HR: 0.70; 95% CI, 0.48–1.00; p=0.049). TTFields showed a low toxicity safety 
profile, as previously reported, with no grade 3/4 device-related adverse events. Conclusion: 
TTFields plus chemotherapy after first disease recurrence on TTFields plus temozolomide or 
temozolomide alone prolonged OS in patients in the EF-14 trial.
First draft submitted: 29 December 2016; Accepted for publication: 6 March 2017; Published 
online: 12 April 2017
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Glioblastoma (GBM) is the most common malignant tumor of the CNS; GBM accounts for 46% 
of primary malignant brain tumors [1], and its aggressive behavior presents unique treatment chal-
lenges. After maximal safe surgical resection, the conventional standard of care is radiotherapy 
with concomitant temozolomide followed by maintenance temozolomide [2]. Despite aggressive 
multimodal therapy, the prognosis of patients with GBM is poor; historically, the 2-year survival 
rate is 27%, and only 10% of patients live longer than 5 years [3]. Therapeutic options are limited 
after progression following initial treatment, and clinical trials of investigational systemic therapies 
in the past decade have failed to improve outcomes of patients with GBM [4–8].
Tumor-treating fields (TTFields) is an approved treatment for patients with GBM that inhib-
its tumor cell growth by blocking cell division and replication. TTFields delivers low-intensity, 
intermediate-frequency (200 kHz) alternating electric fields via transducer arrays applied to the 
shaved scalp [9–16]. In the randomized Phase III trial (EF-14; NCT00916409) of TTFields in newly 
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diagnosed patients with GBM after initial treat-
ment with standard chemoradiation, the combi-
nation of TTFields plus maintenance temozo-
lomide significantly improved progression-free 
survival (PFS) and overall survival (OS) com-
pared with temozolomide alone in a prespeci-
fied interim analysis. Based on the observed 
survival benefits, the Independent Data Safety 
Monitoring Board recommended termination 
of the study [13]. TTFields is the first interven-
tion in a decade to improve survival in patients 
with newly diagnosed GBM and was recently 
approved by the US FDA for use in combination 
with temozolomide [17].
GBM inevitably recurs, and new treatment 
options are needed to manage progressive dis-
ease. A previous randomized Phase III trial (EF-
11; NCT00379470) of TTFields monotherapy 
versus chemotherapy in patients with recurrent 
GBM did not show significant improvement 
in OS and PFS compared with chemotherapy; 
however, quality of life was improved in the 
TTFields group without the usual toxic effects 
associated with chemotherapy [12]. The real-world 
clinical practice setting of the Patient Registry 
Dataset (PRiDe) of 457 patients with recurrent 
GBM who received TTFields demonstrated 
significantly longer median OS compared with 
the EF-11 trial (9.6 vs 6.6 months; hazard ratio 
[HR]: 0.66; 95% CI, 0.05–0.86; p = 0.0003) [18].
The objective of the current post hoc analy-
sis was to evaluate the efficacy and safety of 
TTFields when added to second-line treatment 
according to physician’s best choice after first 
disease recurrence among patients enrolled in 
the EF-14 Phase III trial.
Materials & methods
●● Patient selection & study design
General details of this multicenter, open-label, 
randomized Phase III trial of TTFields plus temo-
zolomide versus temozolomide alone in patients 
with newly diagnosed GBM have previously been 
reported by Stupp et al. [13]. Briefly, patients of 
≥18 years of age with histologically confirmed 
supratentorial GBM, who were progression free 
after having undergone maximal safe debulking 
surgery or biopsy, had completed standard frac-
tionated radiotherapy plus concomitant temozo-
lomide and had a Karnofsky performance status 
(KPS) score of ≥70% were enrolled. All patients 
provided written informed consent, and the insti-
tutional review boards or ethics committees of 
the 83 participating centers approved the study. 
After completion of treatment with temozolo-
mide and radiotherapy, patients were randomized 
(Figure 1) to receive maintenance temozolomide 
(150–200 mg/m2 per day for 5 days, every 28 days 
for 6–12 cycles) [19] with or without TTFields, 
which was to be initiated within 4–7 weeks from 
the last dose of concomitant temozolomide and 
radiotherapy. Patients receiving TTFields were 
fitted with four transducer arrays placed on the 
shaved scalp and connected to a portable, bat-
tery- or power supply-operated device (Optune, 
NovoCure Ltd, Haifa, Israel) set to generate alter-
nating electric fields of 200 kHz within the brain. 
Transducer array placement was individualized to 
deliver optimal field intensity within the treated 
tumor as determined by a TTFields mapping 
software system (NovoTAL, NovoCure Ltd). 
After being trained to operate the device, the 
patient continued treatment at home. Transducer 
arrays were supplied in sterile packaging and 
replaced by the patient, a caregiver or a device 
technician twice per week. Short treatment breaks 
for personal care were allowed.
At first progression, second-line therapy was 
offered per local practice to patients who expe-
rienced tumor progression. Thirteen patients 
randomized into the temozolomide-alone group 
crossed over to receive TTFields plus second-
line chemotherapy following commercial avail-
ability of TTFields for recurrent GBM after 
regulatory approval. Treatment with TTFields 
continued until the second radiologic progres-
sion or clinical deterioration, for a maximum 
of 24 months. The criteria for progression were 
based on the MacDonald criteria [20]: tumor 
growth of >25% of the product of two perpen-
dicular diameters compared with the smallest 
tumor area measured in the patient during the 
trial, and the appearance of one or more new 
tumors in the brain (diagnosed radiologically as 
GBM). The final determination of progression 
was made by independent radiology review in 
cases in which MRI was available. In cases in 
which MRI was not available, clinical progres-
sion was determined according to the following 
criteria: decline in functional status as indicated 
by a decrease of ≥20 points in KPS, decline in 
neurologic function as indicated by a decrease 
of ≥2 points in the Medical Research Council 
scale [21] or an increase of ≥50% in steroid dose.
●● Statistical analysis
A post hoc analysis of OS, computed from the day 
of first progression until event (death) or censored 
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Figure 1. Patient flow. 
TMZ: Temozolomide; TTFields: Tumor-treating fields.
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at the last follow-up, was conducted according 
to the Kaplan–Meier method. Analyses were 
performed for all patients who progressed after 
any treatment. Time to first progression was 
based on the blinded central radiology review. 
All survival comparisons between groups were 
performed using a two-sided log–rank test with 
an α-value of 0.05. All statistical analyses were 
performed using SAS version 9.4 (SAS Institute, 
Inc., NC, USA).
results
●● Patient characteristics
A total of 695 patients with newly diagnosed 
GBM were randomized 2:1 to receive TTFields 
plus temozolomide (n = 466) or temozolomide 
alone (n = 229). Following temozolomide dis-
continuation due to toxicity or radiologic dis-
ease progression, second-line therapy (including 
reoperation, radiosurgery, chemotherapy, bevaci-
zumab or combination therapy) was offered and 
continued until second progression for a maxi-
mum of 24 months. At the time of database lock 
(December 2014), 228 patients (48.9%) in the 
TTFields plus temozolomide group had a first 
recurrence, and 131 patients (28.1%) received 
second-line chemotherapy in addition to contin-
ued TTFields treatment. In the temozolomide-
alone group, 121 patients (52.8%) had a first 
recurrence and 73 patients (31.9%) received 
second-line chemotherapy (Figure 1). Thirteen 
patients out of 73 in the temozolomide-alone 
group crossed over and received second-line 
therapy after disease progression in combina-
tion with TTFields after approval and commer-
cial availability of TTFields for recurrent GBM. 
Therefore, 60 patients were treated with second-
line chemotherapy alone, and 144 patients with 
TTFields plus second-line chemotherapy after 
first disease progression.
Patients’ characteristics were well balanced 
between the two groups (Table 1). Median age 
was 57 years in the TTFields plus chemotherapy 
group and 58 years in the chemotherapy-alone 
group, and 75% of the patients in both groups 
were male. The median KPS score was 90% 
in both groups. About 58 and 57% of patients 
had gross total resection in the TTFields plus 
188  CNS Oncol. (2017) 6(3)
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chemotherapy and chemotherapy-alone groups, 
respectively, and the frequency of MGMT meth-
ylation was 24 and 23%.
●● Choice of second-line therapy
Second-line treatments were well balanced 
between the TTFields plus chemotherapy and 
chemotherapy-alone groups. Bevacizumab 
(monotherapy or in combination with chemo-
therapy) was the most frequently used sec-
ond-line treatment (53% overall; 55% in the 
TTFields plus chemotherapy group; and 50% 
in the chemotherapy-alone group; Table 2). 
Lomustine, carmustine and fotemustine were 
the most frequently used chemotherapy regi-
mens, and were administered in 36 and 38% 
of patients in the TTFields plus chemotherapy 
and chemotherapy-alone groups. Temozolomide 
treatment was continued in 17 and 12% of 
patients in the TTFields plus chemotherapy and 
chemotherapy-alone groups, respectively.
●● Efficacy
After a median follow-up of 12.6 months, 
median OS in patients who received TTFields 
plus chemotherapy after first recurrence was 
11.8 months, compared with 9.2 months in 
patients who received chemotherapy alone 
(HR: 0.70; 95% CI, 0.48–1.00; p = 0.049; 
Figure 2a). As bevacizumab was the most fre-
quent second-line treatment of choice, either 
as monotherapy or in combination with cyto-
toxic chemotherapy, OS was evaluated in the 
subset of patients who received bevacizumab 
with or without TTFields. Median OS from 
first disease recurrence with TTFields plus 
bevacizumab was 11.8 months, compared with 
9.0 months in patients who received bevaci-
zumab without TTFields treatment (HR: 0.61; 
95% CI, 0.37–0.99; p = 0.043; Figure 2B).
●● Safety
Less than half of the patients treated with 
TTFields (49%) experienced at least one grade 
3/4 treatment-emergent adverse event compared 
with 33% of patients who received chemother-
apy alone (Table 3). Frequencies of thrombocy-
topenia, convulsion, hemiparesis, headache and 
mental status changes were numerically higher 
in the TTFields plus chemotherapy group com-
pared with the chemotherapy-alone group. 
Medical device site reaction was reported in 
19 patients (13%) who received treatment with 
TTFields, and none was severe. Epilepsy was 
reported in three patients (2%) in the TTFields 
plus chemotherapy group and two patients (3%) 
in the chemotherapy-alone group; no grade 3/4 
seizures were reported in either group.
Discussion
GBM is a highly aggressive brain tumor with a 
poor prognosis, and TTFields is the first major 
treatment advance in this patient population 
over the past decade. TTFields was approved by 
the FDA as monotherapy for the treatment of 
recurrent GBM based on results from the EF-11 
Table 1. Baseline characteristics.
Characteristic TTFields plus second-line 
chemotherapy (n = 144)
Second-line chemotherapy 
alone (n = 60)
Median age, years (range) 57 (29–83) 58 (22–75)
Sex, n (%):
– Male 108 (75) 45 (75)
– Female 36 (25) 15 (25)
Median Karnofsky performance status 
score (%) (range)
90 (60–100) 90 (70–100)
Extent of resection at the time of diagnosis, n (%):
– Biopsy 20 (14) 10 (17)
– Gross total resection 84 (58) 34 (57)
– Partial resection 40 (28) 16 (27)
MGMT status, n (%):
– Methylated 35 (24) 14 (23)
– Unmethylated 59 (41) 25 (42)
– Invalid 21 (15) 10 (17)
– Unknown 29 (20) 11 (18)
TTFields: Tumor-treating fields.
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trial [12]. A prespecified interim analysis in the 
EF-14 trial demonstrated a significant improve-
ment in median PFS (7.1 vs 4.0 months) and 
OS (20.5 vs 15.6 months) in patients receiving 
TTFields plus standard maintenance temozo-
lomide versus temozolomide alone [13]. Based 
on these positive results, enrollment in the trial 
was terminated, and TTFields was approved by 
the FDA for the treatment of adult patients with 
newly diagnosed GBM [17]. This post hoc analysis 
from the interim analysis population of the EF-14 
trial demonstrated that TTFields significantly 
improves OS when combined with second-line 
treatment after first disease recurrence. NCCN 
guidelines recommend systemic chemotherapy 
and/or bevacizumab for the treatment of recur-
rence [22] and this analysis showed that continued 
treatment with TTFields in addition to second-
line treatment significantly improved OS in this 
patient population. The results suggest that the 
OS benefit from adding TTFields to second-line 
treatment may be independent of the concurrent 
systemic therapy. However, it should be acknowl-
edged that this study provides no information on 
the possible benefit of continuation of TTFields 
alone in this patient population.
The survival durations of the chemotherapy 
group in our analysis are comparable with the 
previously reported data. For example, the 
reported median OS in a pivotal trial of beva-
cizumab for recurrent GBM ranged from 8.7 
to 9.2 months [23], and a recent analysis of real-
world data demonstrated median OS approach-
ing 9 months with a bevacizumab-containing 
treatment in bevacizumab-naive patients initiat-
ing second-line therapy for recurrent GBM [24]. 
In a retrospective analysis of fotemustine as sec-
ond-line treatment for recurrent GBM in elderly 
patients, the median OS from initiation of ther-
apy was 7.1 months [25]. The addition of TTFields 
to bevacizumab or other second-line therapy in 
the current report further extends median OS 
by 2 months beyond that achieved with second-
line treatment alone, and supports earlier results 
from the PRiDe real-world study of the safety 
and efficacy of TTFields (used as monotherapy 
or in combination with systemic treatment[s]) 
in patients with recurrent GBM [18]. A third 
of the patients from PRiDe were treated with 
TTFields after a first recurrence and achieved 
a median OS of 20 months. This was signifi-
cantly longer than that in patients treated at 
their second recurrence (8.5 months) or at their 
third or subsequent recurrence (4.9 months). In 
addition, the PRiDe data established the impor-
tance of treatment compliance for extending OS 
with TTFields (a median OS of 13.5 months 
in patients with ≥75% daily compliance with 
device use vs 4.0 months in patients with <75% 
daily compliance), without any new safety 
signals compared with EF-11. Taken in con-
junction with the previously reported benefits 
with TTFields for newly diagnosed GBM in 
the EF-14 interim analysis [13], our results sup-
port the early initiation and continued use of 
TTFields in combination with standard systemic 
therapies for the treatment of GBM.
The toxicity profile was similar in patients 
treated with TTFields plus chemotherapy after 
first recurrence compared with patients treated 
with TTFields plus temozolomide as mainte-
nance therapy [13]. A numerically higher inci-
dence of adverse events in the TTFields group 
could have been a consequence of the longer 
duration of follow-up compared with the patients 
treated with chemotherapy alone. Notably, there 
were no reported incidences of grade 3/4 seizure 
in either group in the current study. In addi-
tion, only 13% of patients treated with TTFields 
reported a medical device site reaction, and none 
Table 2. Type of second-line chemotherapy after first recurrence.
Second-line chemotherapy TTFields plus second-line 
chemotherapy (n = 144); n (%)
Second-line chemotherapy 
alone (n = 60); n (%)
Bevacizumab: 
– Monotherapy 61 (42) 26 (43)
– Combination therapy 18 (13) 4 (7) 
Lomustine, carmustine, fotemustine 52 (36) 23 (38)
Temozolomide 25 (17) 7 (12)
Irinotecan 3 (2) 2 (3)
Carboplatin 3 (2) 1 (2)
Procarbazine 0 1 (2)
TTFields: Tumor-treating fields.
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Figure 2. overall survival from first disease recurrence. (a) TTFields plus second-line chemotherapy 
versus second-line chemotherapy alone, or (B) TTFields plus bevacizumab alone or in combination 
with chemotherapy versus bevacizumab alone or in combination with chemotherapy. 
HR: Hazard ratio; OS: Overall survival; TTFields: Tumor-treating fields.
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was severe. Patients usually tolerate the Optune 
device well, without adverse effects on quality 
of life, cognitive or functional capabilities with 
equal cognitive, emotional, physical and social 
functioning scores, and superior global health 
status ratings to the control arm demonstrated 
in the EF-14 study [26,27]. These data support the 
continued use of TTFields plus chemotherapy 
after first recurrence.
Prospective trials are currently underway to 
evaluate the administration of TTFields plus 
bevacizumab to patients with GBM, includ-
ing in patients with newly diagnosed unresect-
able GBM in combination with temozolomide 
(NCT0234359), in patients with recurrent 
GBM (NCT01894061 and NCT02663271) 
and in patients with bevacizumab-refractory 
recurrent GBM (NCT02743078). These stud-
ies will provide additional insight into the effi-
cacy and safety of TTFields in combination 
with bevacizumab as first-line and second-line 
therapy for GBM. In addition, ongoing analyses 
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of biomarker data from the EF-14 trial may help 
identify the subset(s) of patients most likely to 
benefit from continued TTFields treatment in 
combination with standard of care.
It is important to note that these results are 
limited by the post hoc nature of the analyses 
and by the fact that the second-line TTFields 
group was heterogeneous for prior treatment 
history (i.e., included a small subset of patients 
who had initiated TTFields at first recurrence 
in addition to a larger group of patients who 
had received TTFields upfront). Moreover, most 
of the patients who continued TTFields after 
recurrence had relapsed after first-line TTFields 
therapy, and the choice of second-line systemic 
therapy was based on local practice; these factors 
may have had confounding effects. Nonetheless, 
the concordance in median OS results between 
the chemotherapy groups in our analysis and 
earlier reports [23–25] supports the validity of 
these results. Overall, our report supports the 
continued use of TTFields in patients with GBM 
after first disease recurrence.
Conclusion
This post hoc analysis suggests that treatment 
with TTFields improves OS when combined 
with second-line treatment after f irst dis-
ease recurrence. Continued treatment with 
TTFields in addition to second-line treatment 
with bevacizumab with or without concomi-
tant chemotherapy also significantly improved 
OS, indicating that the OS benefit from add-
ing TTFields to second-line treatment may 
be independent of the systemic therapy being 
used. It is important to note that these results 
are limited by the post hoc nature of the analyses 
and by the fact that the second-line TTFields 
group included a small proportion of patients 
who did not receive TTFields as initial therapy. 
Overall, our report supports the continued use 
of TTFields in patients with GBM after first 
disease recurrence.
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exeCuTive summary
Background
 ●  Tumor-treating fields (TTFields) is an approved treatment for adults with glioblastoma (GBM), combined with 
temozolomide as maintenance treatment in newly diagnosed patients and as monotherapy for recurrent disease.
 ●  TTFields delivers low-intensity, intermediate-frequency alternating electric fields that inhibit tumor growth by 
blocking cell division and replication.
Design of study
 ●  The EF-14 trial in patients with newly diagnosed GBM showed that the combination of TTFields and maintenance 
temozolomide (after initial chemoradiation) significantly increases progression-free survival and overall survival (OS) 
compared with maintenance temozolomide alone.
 ●  This post hoc analysis was designed to evaluate the efficacy and safety of TTFields combined with second-line therapy 
after first recurrence in patients included in EF-14.
Key results
 ●  After first progression, 131 patients in the original TTFields plus temozolomide arm continued with TTFields and a 
further 13 patients in the temozolomide-alone arm crossed over to TTFields combined with physician’s choice of 
second-line therapy. Sixty patients in the temozolomide-alone arm received second-line systemic therapy alone after 
progression.
 ●  Second-line treatments were similar between the two groups, with bevacizumab alone or in combination the most 
frequent choice.
 ●  After a median follow-up of 12.6 months, the median OS was 11.8 months in the patients who received TTFields plus 
chemotherapy compared with 9.2 months in those who received chemotherapy alone (HR: 0.70; 95% CI: 0.48–1.00; 
p = 0.049).
 ●  Treatment with TTFields was well tolerated with a similar toxicity profile to that previously reported.
Conclusion & clinical significance
 ●  This post hoc analysis showed that TTFields combined with second-line treatment significantly increased OS after first 
recurrence of GBM.
 ●  The benefit of TTFields appeared independently of the second-line therapy used.
 ●  The results support the continued use of TTFields after first relapse.
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